U.S. Markets open in 2 hrs 23 mins

Why This Biotech Stock Looks Prime For A Johnson & Johnson Buyout

ALLISON GATLIN
Why This Biotech Stock Looks Prime For A Johnson & Johnson Buyout

Dow Jones component Johnson & Johnson could buy out biotech stock MeiraGTx for its efforts in gene therapy, an analyst suggested Friday. MeiraGTx is working on treatments for eye diseases.